Expression of VCAM1 on the endothelial cells that line the blood-brain barrier allowed aging factors in the plasma to exact their toll on the brain.
Lanabecestat, elenbecestat, and umibecestat all showed data at the AD/PD conference in Lisbon. Learn what definitely doesn’t work and what might yet.
Long recognized in dendrites, scientists now report that substantial synaptic proteome remodeling happens on the axonal side, too.
More mouse data add to the argument that a flashing light sequence could potentially fight cognitive decline.
The global agency’s report recommends physical activity, a healthy diet, stopping alcohol abuse and smoking, and managing one’s weight, blood pressure, and diabetes.
“We are learning” was the tenor of debate about the latest round of setbacks for anti-amyloid trials in symptomatic Alzheimer’s disease at a recent conference in Lisbon.
An electron microscopy study reveals a jumbled mess of membrane chunks and malfunctioning organelles, bound together by phosphorylated or truncated α-synuclein.
At AD/PD 2019, scientists implicated both peripheral and central innate immunity in promoting propagation.
Virtual Exhibit Hall
Alzforum encourages users to visit the Virtual Exhibit Hall, where companies showcase their newest initiatives, products, and services. We welcome Dash Genomics, Inc. and Abcam, which join our other exhibitors — Biogen, BioLegend, BrainXell, NanoString Technologies, and the Jackson Laboratory.
We have concluded coverage from the 14th AD/PD conference held earlier this spring in Lisbon, Portugal. Our 16-part series runs the gamut from genetics to innate immune cells, from ApoE to lipids, from the search for diagnostic tests to the basic science of endocytosis and α-synuclein. We covered the pursuit of new therapeutic targets, as well as the painful harvest currently being reaped from Phase 3 anti-amyloid trials. On that, scientists at different companies were sharing detailed results from each other’s programs in hopes of learning as they "fall forward toward success." Crenezumab, lanabecestat, aducanumab are the latest official casualties; AD/PD offered data on the first two. Despite obituaries in the analyst press, the amyloid hypothesis is not dead. Gantenerumab, BAN2401, elenbecestat, umibecestat, and CAD106 are in late-stage trials, and crenezumab and solanezumab are still being evaluated in presymptomatic AD. See AD/PD Parts 15, 16.
The 2019 AD/PD conference in Lisbon showcased the latest in Parkinson’s research, including new glimpses into the behavior of pathologic α-synuclein. Among the surprises: Peripheral and central immune cells may promote the spread of pathology, challenging the hypothesis of templated seeding as the primary mechanism. In mouse models, macrophages in the gut trigger α-synuclein accumulation there, which then spreads to the brain. Within the brain, α-synuclein transmission was linked to microglial activation. Surprise number two: Lewy bodies, rather than being primarily fibrillar, are mostly fat. Researchers vizualized a mass of undigested membrane fragments and organelles bound together with phosphorylated and truncated α-synuclein.
- Heinz Hillen on BACE Inhibitors: Postmortem on One, Live Updates on Two
- Dante Marciani on Keep Your Enthusiasm? Scientists Process Brutal Trial Data
- Celia Williams on Plasticity Hums With Protein Synthesis on Both Sides of Synapse
- Marvin Berman on Gamma Waves Synchronized by Light: Good for Synapses, Memory?
- Christos Proukakis on Single-cell transcriptomic analysis of Alzheimer's disease.
- Ulrich Hengst on Plasticity Hums With Protein Synthesis on Both Sides of Synapse
- John Breitner on Antibodies Against Microglial Receptors TREM2 and CD33 Head to Trials
- Logan Schneider on Drug Reported to Help Alzheimer’s Patients Sleep Better
- Tim Bartels on Forget Fibrils: Lewy Pathology Is More Lipid Than Protein
- Tiago Outeiro on Forget Fibrils: Lewy Pathology Is More Lipid Than Protein
- Gil Rabinovici on Longitudinal Tau-PET Links Aβ to Subsequent Rise in Cortical Tau
- Ruth Itzhaki on On The Docket at AD/PD: The Many Crimes of ApoE4
- Brian Draper on Amyloid-PET Results Lead Some to Ponder Assisted Death in Future
- Joshua Grill on Amyloid-PET Results Lead Some to Ponder Assisted Death in Future
- Steve Barger on On The Docket at AD/PD: The Many Crimes of ApoE4
- Davide Vito Moretti on Introducing LATE—A Common TDP-43 Proteinopathy that Strikes After 80
- Michael Lardelli on Alternative splicing in a presenilin 2 variant associated with Alzheimer disease.
- Peter Nelson on Introducing LATE—A Common TDP-43 Proteinopathy that Strikes After 80
- Michelle Mielke on Plasma NfL Goes the Distance in Alzheimer’s
- Philip Weston on Plasma NfL Goes the Distance in Alzheimer’s
- Brian Gordon on Plasma NfL Goes the Distance in Alzheimer’s